Stock Price & Analysis

Based on the provided data and recent market activity, here's a concise analysis of AZN stock:

Technical Analysis The stock is currently trading at $69.06, showing positive momentum with gains across pre-market (+0.70%), regular market (+0.67%), and post-market (+0.38%) sessions. The RSI-14 reading of 63.37 indicates moderate bullish momentum without being overbought. The positive MACD of 0.38 suggests an upward trend continuation.

Recent Developments

• AstraZeneca announced a significant CA$820 million investment in Canada, creating over 700 jobs and expanding their Toronto operations. This strategic move aligns with their goal of achieving $80 billion in total revenue by 2030.
• The company is restructuring its leadership in China following investigations involving former country president Leon Wang, which has created some near-term uncertainty in this important market.

Analyst Perspective UBS upgraded AstraZeneca from Strong Sell to Hold in November 2024, citing that while China uncertainty exists, a wholesale loss of AstraZeneca's franchise seems unlikely.

Growth Outlook

• The company has set ambitious targets to achieve $80 billion in revenue by 2030
• Seven Phase 3 clinical trial data readouts expected in 2025
• Strong presence in oncology with 19% year-over-year growth in Q3 2024

Buy/Sell Decision Given the current price level and positive momentum, coupled with strong fundamentals and strategic investments, AZN appears to be a moderate buy. The stock shows resilience despite China-related challenges, and the company's robust pipeline and expansion plans support long-term growth potential.

Based on the provided data and references, here is the price prediction analysis for AstraZeneca (AZN) stock in 2025:

Technical Analysis The stock is currently trading at $69.06 with RSI at 63.37, indicating a moderately bullish momentum but not yet overbought. The 20-day moving average at $66.67 acts as a support level, with the stock trading above it, suggesting an upward trend.

Fundamental Drivers

1. Growth Target: AstraZeneca aims to achieve $80 billion in total revenue by 2030, representing significant growth potential from current levels.

2. Strategic Investments: The company recently announced a CA$820 million ($570 million) investment in Canada, creating over 700 jobs. This expansion supports their global growth ambitions.

3. Pipeline Progress: The company expects seven first Phase 3 clinical trial data readouts in 2025, which could potentially drive stock movement based on results.

Price Target 2025 Based on the analysis of current trends and fundamental factors:

The stock is expected to reach $90 by end of 2025, representing a ~30% upside from current levels. This projection is supported by:

• Forward P/E multiple expansion to 17x (from current 14x) as the company executes on growth initiatives
• Expected earnings growth of 13.22%
• Strong pipeline developments and geographical expansion plans

The primary risk factor is the ongoing investigation in China, but the company's diversified geographic presence and strong product portfolio should help mitigate this impact.

The S1 support level for AZN Stock is $64.93 ,The R1 resistant level for AZN Stock is $68.94.

As of the end of day on 2025-01-24, the price of AZN Stock was $69.

The target price for AZN Stock according to analyst rating is 87.67, with the highest price target at 88.00 and the lowest at 87.00. Analysts have a Strong Buy rating on AZN Stock overall.

The market cap of AZN is $214.2B.

Based on the provided data and recent market developments, here's a concise analysis of AstraZeneca's valuation:

Valuation Analysis: AstraZeneca appears fairly valued with some concerns. The stock trades at a P/E of 37.5x (Q3 2024), which is significantly higher than the pharmaceutical industry average. However, this premium valuation needs to be viewed in context of several factors:

Growth & Profitability Trends:

• Revenue shows healthy growth from $12.7B to $13.6B over Q1-Q3 2024
• However, net income declined from $2.2B to $1.4B in the same period
• Net margin contracted significantly from 17.2% to 10.6%

Key Concerns:

• Recent management issues in China operations could impact future growth
• China revenue accounts for 5-6% of total sales, presenting some risk
• Operating margins showing pressure in recent quarters

Positive Factors:

• Strong investment in Canada ($820M) announced recently, creating 700+ jobs
• Robust drug pipeline with multiple late-stage clinical trial readouts expected in 2025
• Global revenue target of $80B by 2030 shows ambitious growth plans

Conclusion: At current valuation levels, AZN appears slightly overvalued given the declining profitability metrics and China-related risks. The premium multiple isn't fully justified by current growth and margin trends.

AstraZeneca PLC is a science-led biopharmaceutical company. It discovers, develops, and commercializes prescription medicines in oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal and metabolism, respiratory and immunology and vaccines and immune therapies. Its key marketed oncology products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Zoladex, Faslodex and others. Its rare diseases products include Soliris, Ultomiris, Strensiq and Kanuma. Its biopharmaceuticals products include Farxiga, Crestor, Breztri and others. Its investigational vaccine candidate IVX-A12, which targets both respiratory syncytial virus and human metapneumovirus. Its oncology candidate includes FPI-2265 targeting prostate specific membrane antigen for metastatic castration resistant prostate cancer, which is in a Phase II trial. It also discovers, develops, and manufactures T-cell receptor therapies. Its Eneboparatide is an investigational therapeutic peptide.

Based on the provided data and market research, here's the analysis for AstraZeneca's (AZN) stock price prediction for 2030:

AstraZeneca's stock price is projected to reach $120-130 by 2030, driven by three key factors:

1. Revenue Growth Target: The company has set an ambitious target of achieving $80 billion in revenue by 2030. With current strong performance showing 18.57% year-over-year revenue growth and expanding margins, this goal appears achievable despite recent challenges.

2. Pipeline Strength: AstraZeneca's robust pipeline includes multiple late-stage clinical trials scheduled for 2025, with potential new drugs that could generate $25 billion in sales. The company is also making strategic moves in the weight management sector and expanding its global manufacturing footprint.

3. Geographic Expansion: Strategic investments of $3.5 billion in U.S. manufacturing and R&D, plus €1.3 billion in their Barcelona hub, demonstrate strong commitment to market diversification and growth.

The price target is based on:

• Projected 2030 EPS of $8-9 (assuming 13-15% annual growth from current $4.11 EPS)
• Forward P/E multiple of 15-16x (conservative compared to current industry average)
• Continued dividend growth maintaining yield around 2%

AZN has a total of 89900 employees.